A study of gemtuzumab ozogamicin in combination with G-CSF after CAG or MEC (CA-G-GO therapy or MEC-G-GO therapy) for relapsed or refractory acute myeloid leukemia.

Trial Profile

A study of gemtuzumab ozogamicin in combination with G-CSF after CAG or MEC (CA-G-GO therapy or MEC-G-GO therapy) for relapsed or refractory acute myeloid leukemia.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 May 2017

At a glance

  • Drugs Gemtuzumab ozogamicin (Primary) ; Granulocyte colony-stimulating factors (Primary) ; Aclarubicin; Cytarabine; Etoposide; Filgrastim; Mitoxantrone
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top